Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma will spread, Mount Sinai researchers report.

Patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports. 

“Our study is the first to characterize the tumor-suppressive functions of ARID2 in melanoma,” says the study’s lead author Emily Bernstein, PhD, Professor of Oncological Sciences at The Tisch Cancer Institute at Mount Sinai, in a news letter. “We modeled ARID2 mutations by removing the ARID2 protein completely from melanoma cells and studied the consequences in the petri dish and in animal models. Recreating actual mutations that patients harbor is challenging, but now possible by genome editing, and would further provide a more accurate model; such studies are ongoing in the lab.”

ARID2 is part of a chromatin remodeling complex and frequently mutated in melanoma. In this study, scientists used melanoma tumor models to measure the role of the ARID2 gene in cancer progression. They assessed the effects of ARID2 loss on the epigenetic landscape, a dynamic DNA and protein platform that provides molecular instructions on gene expression, which in turn shapes cellular functions and behaviors. They found that without ARID2, melanoma cells exhibit increased metastatic behaviors.